ISRA - ETF AI Analysis
Top Page
VanEck Israel ETF (ISRA)
Rating:70Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown solid gains so far this year and in recent months, indicating positive momentum.
Several Strong Top Holdings
Many of the largest positions, including key technology, defense, and financial names, have delivered strong year-to-date performance that supports the fund’s returns.
Broad Sector Diversification
Holdings spread across financials, technology, health care, industrials, and other sectors help reduce the impact of weakness in any single industry.
Negative Factors
High Country Concentration
The fund is heavily focused on Israel with only limited exposure to other countries, which increases its sensitivity to Israel-specific economic and geopolitical risks.
Financial Sector Heavy Weighting
A large share of the portfolio is in financial stocks, so a downturn in banks or financial services could hurt the ETF more than a more balanced fund.
Above-Average Expense Ratio
The fund’s expense ratio is relatively high for an ETF, which means more of the returns are used to cover fees instead of going to investors.
ISRA vs. SPDR S&P 500 ETF (SPY)
AUM154.80M
RegionMiddle East & Africa
Expense Ratio0.59%
Beta0.83
IssuerVanEck
Inception DateJun 25, 2013
Dividend Yield1.33%
Asset ClassEquity
Index TrackedBlueStar Israel Global Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,738
30 Day Avg. Volume8,111
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ISRA Summary
The VanEck Israel ETF (ISRA) tracks the BlueStar Israel Global Index and gives you broad exposure to Israeli companies, including many listed in the U.S. It holds a mix of banks, tech, and health care firms, from large players to smaller innovators. Well-known holdings include Teva Pharmaceutical and Check Point Software. Someone might invest in ISRA to tap into Israel’s reputation as a “Start-Up Nation” and to diversify beyond the U.S. market. A key risk is that it is concentrated in one country, so it can go up and down with the Israeli market and regional tensions.
How much will it cost me?The VanEck Israel ETF (ISRA) has an expense ratio of 0.59%, which means you’ll pay $5.90 per year for every $1,000 invested. This is slightly higher than average because the fund is focused on a specific niche market (Israeli securities) and requires more active management compared to broad, passively managed index funds.
What would affect this ETF?The VanEck Israel ETF (ISRA) could benefit from Israel's strong reputation in technology and innovation, particularly in cybersecurity, biotechnology, and clean energy, which are key drivers of growth. However, potential risks include geopolitical tensions in the Middle East and global economic slowdowns, which could negatively impact the financial and industrial sectors that make up a significant portion of the ETF's holdings.
ISRA Top 10 Holdings
ISRA’s story is all about Israel’s tech engine, with Palo Alto Networks, Tower Semiconductor, Nova, and JFrog doing most of the heavy lifting as their shares have been steadily rising and, in some cases, sprinting ahead. On the flip side, big Israeli banks like Leumi, Poalim, and Mizrahi Tefahot are losing steam, acting as a brake on the fund’s momentum. Teva and Elbit sit somewhere in the middle with more mixed signals. Overall, this is a tech-tilted, Israel-only play, not a globally diversified mix.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Palo Alto Networks | 13.04% | $20.19M | $234.54B | 40.86% | 73 Outperform | |
| Teva Pharmaceutical | 6.74% | $10.43M | $37.14B | 89.75% | 63 Neutral | |
| Leumi | 5.28% | $8.17M | ₪96.38B | 15.41% | 80 Outperform | |
| Poalim | 4.78% | $7.40M | ₪88.50B | 14.54% | 79 Outperform | |
| Tower | 4.13% | $6.39M | $32.05B | 689.95% | 76 Outperform | |
| Elbit Systems | 4.12% | $6.38M | ₪109.96B | 50.92% | 73 Outperform | |
| Phoenix | 2.23% | $3.45M | ₪41.21B | 90.06% | 79 Outperform | |
| JFrog | 2.22% | $3.44M | $10.02B | 92.41% | 73 Outperform | |
| Nova | 2.09% | $3.23M | $18.29B | 149.08% | 81 Outperform | |
| Discount | 2.03% | $3.14M | ₪35.14B | -5.76% | 75 Outperform |
ISRA Technical Analysis
Positive
―
Price Trends
66.65
Positive
64.94
Positive
61.11
Positive
Market Momentum
-0.48
Negative
56.52
Neutral
90.29
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ISRA, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 64.45, equal to the 50-day MA of 66.65, and equal to the 200-day MA of 61.11, indicating a bullish trend. The MACD of -0.48 indicates Negative momentum. The RSI at 56.52 is Neutral, neither overbought nor oversold. The STOCH value of 90.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ISRA.
ISRA Peer Comparison
Comparison Results
Performance Comparison
ISRA
VanEck Israel ETF
66.65
14.80
28.54%
IMFL
Invesco International Developed Dynamic Multifactor ETF
―
―
―
JHMD
John Hancock Multifactor Developed International ETF
―
―
―
SYLD
Cambria Shareholder Yield ETF
―
―
―
FDMO
Fidelity Momentum Factor ETF
―
―
―
EIS
iShares MSCI Israel ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents